Barclays Cuts Twist Bioscience (NASDAQ:TWST) Price Target to $52.00

Twist Bioscience (NASDAQ:TWST) had its price objective cut by Barclays from $55.00 to $52.00 in a research report released on Tuesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other equities analysts have also recently issued research reports about the company. Evercore ISI upped their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. JPMorgan Chase & Co. boosted their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Robert W. Baird raised their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday. Scotiabank upped their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday. Finally, Leerink Partners raised their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.78.

Twist Bioscience Trading Up 1.9 %

TWST stock opened at $41.89 on Tuesday. The stock has a market capitalization of $2.49 billion, a P/E ratio of -11.57 and a beta of 1.78. The firm has a 50-day moving average price of $43.93 and a 200-day moving average price of $46.15. Twist Bioscience has a 12 month low of $23.07 and a 12 month high of $60.90.

Insider Buying and Selling

In other news, CAO Robert F. Werner sold 1,448 shares of Twist Bioscience stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the transaction, the chief accounting officer now directly owns 45,620 shares in the company, valued at approximately $2,034,652. The trade was a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert Chess sold 3,600 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $47.26, for a total value of $170,136.00. Following the sale, the director now directly owns 21,641 shares in the company, valued at $1,022,753.66. This trade represents a 14.26 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is owned by company insiders.

Institutional Trading of Twist Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of TWST. Geode Capital Management LLC raised its stake in Twist Bioscience by 1.9% in the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after purchasing an additional 26,145 shares in the last quarter. Barclays PLC lifted its holdings in shares of Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after acquiring an additional 104,420 shares during the last quarter. XTX Topco Ltd grew its position in Twist Bioscience by 36.7% in the third quarter. XTX Topco Ltd now owns 15,518 shares of the company’s stock worth $701,000 after acquiring an additional 4,169 shares in the last quarter. Wellington Management Group LLP raised its position in Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after purchasing an additional 521,272 shares in the last quarter. Finally, State Street Corp raised its position in Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.